Welcome to call or send an email!
Petra Larson, Communications lead
+46 (0)709 13 10 08
petra.larson@pharmnovo.com
CONNECT WITH US
Get in touch
Welcome to call or send an email!
Petra Larson, Communications lead
+46 (0)709 13 10 08
petra.larson@pharmnovo.com
Find us: PharmNovo AB, Medicon Village AB, Scheeletorget 1, SE-223 81 Lund, Sweden
PharmNovo is very pleased to announce that we have been awarded a 2.5m EUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read moreOn May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read moreThe final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read moreBengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
